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Objectives: Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z®, Alcon 
Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating 
a formulation of travoprost that would maintain the intraocular pressure (IOP)-lowering efficacy 
and have an improved overall safety profile, particularly improved ocular surface tolerability.
Methods: Thirty newly diagnosed primary open-angle glaucoma (POAG) patients were treated 
with BAK-free travoprost 0.004%. IOP readings were recorded at baseline before initiating 
  treatment, at 4–6 weeks, and after 12 weeks of starting treatment. In addition, patient demo-
graphics, subjective symptoms (ie, burning, foreign-body sensation, itching, and stinging), and 
objective clinical signs such as conjunctival hyperemia were collected. Subjective symptoms were 
evaluated using a four-point scale ranging from “no symptoms,” “mild symptoms,” “moderate 
symptoms” to “severe symptoms.” As for clinical signs, severity of conjunctival hyperemia was 
evaluated. All other adverse events were collected.
Results: BAK-free travoprost 0.004% provided an IOP decrease in all patients, with an overall 
mean of 28.3 ± 2.1 mmHg at baseline to a mean of 18.7 ± 1.6 mmHg at 4–6 weeks, and a mean 
of 18.4 ± 1.4 mmHg after 12 weeks. Both subjective symptoms and objective clinical signs 
were very few after treatment.
Conclusion: The results demonstrate that BAK-free travoprost 0.004% is an effective, well 
tolerated, and safe medication in POAG patients.
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Introduction
Glaucoma is the second leading cause of blindness worldwide. Increased intraocular 
pressure (IOP) is considered to be the most important risk factor and the only one that 
can be modified. Major outcome studies published in recent years have shown that 
lowering IOP is beneficial for patients with primary open-angle glaucoma (POAG).1 
Worldwide, prostaglandins have become a major therapeutic class for medical treat-
ment of glaucoma because of their excellent efficacy and favorable safety profile.2 
However, many prostaglandin analogs contain preservatives that may be toxic to the 
eye. The most common preservative in IOP-lowering medications is benzalkonium 
chloride (BAK), a quaternary ammonium compound that causes bacterial cell death 
by lysing cytoplasmic membranes.3
BAK has demonstrated toxicity against both corneal and conjunctival cells when 
administered in the range of concentrations present in ophthalmic medications 
(0.004%–0.020%). Moreover, in vitro, animal, and clinical studies have demonstrated 
that BAK-containing medications are associated with greater toxicity, increased   Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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ocular surface damage, and decreased tolerability compared 
with BAK-free preparations.4 Instead of using BAK as a 
  preservative, BAK-free travoprost 0.004% (Travatan Z®, 
Alcon Laboratories, Inc, Fort Worth, TX) contains the alterna-
tive preservative system SofZia™ (Alcon Laboratories, Inc), 
containing borate, zinc, and sorbitol.5
Although limited research has been published on SofZia, 
a relatively new preservative, available studies report no 
significant difference in ocular toxicity between travoprost 
BAK-free and preservative-free artificial tears.6 Both in-vitro 
and in-vivo studies directly comparing travoprost BAK-free 
with latanoprost, show that travoprost BAK-free is less toxic 
to the cornea and conjunctiva.7 In addition, a transition study 
by Horsley and Kahook8 also reported that patients with 
reduced tear breakup time who transitioned to travoprost 
BAK-free monotherapy after at least 1 year of latanoprost 
monotherapy had decreased corneal staining, longer tear 
breakup time, and fewer ocular surface disease symptoms, 
while maintaining equivalent IOP-lowering efficacy. 
  Therefore, the goal of the current study was to examine the 
efficacy, safety, and tolerability of travoprost 0.004% BAK-
free in patients with POAG.
Patients and methods
In this open-label study, 30 newly diagnosed patients with 
POAG were followed up for 12 weeks after starting them 
on travoprost 0.004% BAK-free once daily. The initiation 
of this treatment modality was based on the decision of the 
physician only. Consent forms were not required since the 
drug was already approved for ophthalmic use; however,   
verbal consent for commencing the treatment was obtained 
from the patients before starting them on treatment.
exclusion criteria
Patients with previous history of corneal refractive surgery, 
wearing contact lenses, or having clinically significant ocu-
lar surface diseases at baseline such as blepharitis, ocular 
seasonal allergy, or dry eye were excluded from the study. 
Other exclusion criteria included patients chronically using 
ocular medications other than the study medication such 
as artificial tears or antihistamines, and patients who were 
pregnant or nursing or who could become pregnant during 
the study were also excluded. Patients with IOP higher than 
30 mmHg at baseline visit or those who had undergone 
glaucoma filtrating surgeries were also excluded.
Using a standardized data collection form, medical data 
were collected for the patients’ that required an initiation 
of an IOP-lowering therapy to achieve IOP control. Others 
were kept anonymous. Clinical examination data like IOP 
readings were recorded. IOP measurements were made using 
Goldman applanation tonometry for each eye at baseline 
(prior to starting treatment), at 4–6 weeks, and 12 weeks 
after starting treatment with travoprost 0.004% BAK-free 
eye drops. All measurements were recorded at 4:00 PM to 
avoid any diurnal variations of the IOP. All adverse events 
were recorded.
statistical methods
Data were statistically described in terms of mean ± standard 
deviation, frequencies (number of cases), and percent-
ages when appropriate. Data distribution was tested using 
  Kolmogorov Smirnov test. Since numerical data were not 
violating normal assumption, comparison between the 
study groups was done using Student t-test for independent 
samples. Exact test was used instead when the expected 
frequency was less than 5. P-values less than 0.05 were 
Table 1 Patient demographics
Patient (n) 30 (60 eyes)
Mean age 58.9 ± 3.4 years
Gender
  Male (n = 14; 46.7%)
  Female (n = 16; 53.3%)
Note: Characteristics of the patient population included in the study.
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Figure 1 Mean iOP at baseline, 4–6 weeks, and 12 weeks.
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considered statistically significant. All statistical calculations 
were done using SPSS Statistics (SPSS Inc, Chicago, IL) 
software, version 15 for Microsoft Windows.
Results
Patient population
Thirty patients (60 eyes) were included in the study (Table 1). 
The majority of the patients (N = 16; 53.3%) were females. 
All patients were diagnosed with POAG upon commencing 
therapy.
effect on iOP
Overall, mean IOP was 28.3 ± 2.1 mmHg at baseline. Four 
to six weeks after treatment, overall mean IOP was reduced 
to a mean of 18.7 ± 1.6 mmHg and after 12 weeks to a mean 
of 18.4 ± 1.4 mmHg. At both 4–6 weeks and 12 weeks, 
overall, treated IOP values were significantly lower than 
baseline values (P-values = 0.023 and 0.018 respectively). 
The IOP reduction is equivalent to 33.9% and 34.9% from 
treated baseline, respectively (Figure 1).
subjective signs and clinical symptoms
All patients (N = 30, 100%) indicated they tolerated travo-
prost 0.004% BAK-free quite well. None of them discon-
tinued their eye drops during the 3-month follow-up period, 
and all responded to their treatment (IOP reduction noted 
in 100% of patients). Subjective symptoms like irritation, 
t  earing, burning, and stinging were few by the end of the 
study period (12 weeks of treatment).
The most important clinical sign was hyperemia. It was 
reduced over the 3-month treatment period significantly from 
seven patients (23.3% at 6 weeks) to only one patient (3.3%) 
having mild to moderate degree of hyperemia at 12 weeks 
(Figure 2). Systemic tolerability was also noted, and most 
patients did not report any complications because of that.
Discussion
The results of this open-label study demonstrate that tra-
voprost 0.004% BAK-free can achieve good IOP control. 
Travoprost 0.004% BAK-free lowered mean IOP signifi-
cantly compared with the mean pretreatment IOP levels from 
28.3 ± 2.1 mmHg at baseline to 18.7 ± 1.6 mmHg (33.9%) 
at 4–6 weeks and 18.4 ± 1.4 mmHg (34.9%) at final visit 
(12 weeks). A similar effect was found by Uusitalo et al in 
patients after a washout period for their prior medications.9 
A large body of evidence from experimental and clinical 
studies exists, showing that the long-term use of topical drugs 
containing BAK as a preservative may induce changes of 
the ocular surface, tear film instability, epithelial apoptosis, 
conjunctival inflammation, and loss of goblet cells.6
After continuing to use travoprost 0.004% BAK-free, 
subjective symptoms and clinical signs as well as local toler-
ability improved in most patients, and overall patient satisfac-
tion with their glaucoma treatment increased. The authors of 
this paper assumed that the further reduction in the IOP and 
the improvement in the subjective symptoms and hyperemia 
at the end of the study period (12 weeks) compared with the 
6 weeks evaluation visit was due to better compliance of the 
patients to their treatment.
Consistent with previous reports,10 the results of this pres-
ent study suggest that patients with irritation of the   ocular 
surface, ie, subjective symptoms like burning,   stinging, 
foreign body sensation, dry eye, and clinical changes of 
the eye surface (ie, hyperemia) may benefit from a change 
of medication to the travoprost 0.004% BAK-free as it has 
proved a high level of local tolerability and a marked decrease 
in subjective symptoms and clinical signs during the study 
period (12 weeks).
Gandolfi et al11 reported in their study that the intraocular 
pressure IOP-lowering effect of travoprost 0.004% BAK-free 
is noninferior to that of travoprost 0.004% preserved with 
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Figure 2 Frequency and severity of ocular symptoms and hyperemia at 6 and 12 weeks.Clinical Ophthalmology
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BAK (travoprost BAK) in patients with ocular hypertension 
or open-angle glaucoma. Mean IOP reductions from baseline 
ranged from 7.6 to 8.7 mmHg in the travoprost BAK-free 
group and from 7.7 to 9.2 mmHg in the travoprost BAK 
group. The safety profile of travoprost BAK-free was similar 
to that of travoprost BAK.
This study is limited by its open-label design. The 
observed IOP reduction might be ascribed to the improve-
ment of subjective symptoms and clinical signs and thus a 
better compliance. The results identify several factors associ-
ated with the use of travoprost 0.004% BAK-free, such as an 
improvement in subjective symptoms and clinical signs over 
the study period. The study data further suggest that a change 
of a monotherapy treatment regimen to travoprost 0.004% 
BAK-free is worthwhile for patients who are responding 
inadequately to another monotherapy treatment regimen if 
it is attributed to poor patients’ compliance because of their 
local intolerability.
A detailed analysis of the effects of travoprost 0.004% 
BAK-free used in concomitant therapy or as add-on to an 
existing medical treatment was not done in this study due to 
the limited number of patients. Further studies with higher 
numbers of patients are necessary to determine what aspects 
of travoprost 0.004% BAK-free account for the observed 
treatment effects.
Conclusion
In this study, travoprost 0.004% BAK-free was effective, 
well tolerated, and associated with few adverse effects in 
POAG patients. A change of medical therapy to travoprost 
0.004% BAK-free may be beneficial, especially for patients 
with subjective ocular symptoms and/or clinical signs, 
patients with sensitive or dry eyes, and also patients who are 
not responding adequately to other monotherapy treatment 
regimens since the new formulation (travoprost 0.004% 
BAK-free) demonstrated a high degree of local tolerability 
with marked decrease in subjective symptoms and clinical 
signs over the study period (3 months).
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